Fremanezumab—A Humanized Monoclonal Anti-CGRP Antibody—Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Calcitonin gene-related peptide (CGRP), the most abundant neuropeptide in primary afferent sensory neurons, is strongly implicated in the pathophysiology of migraine headache, but its role in migraine is still equivocal. As a new approach to migraine treatment, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs) were developed to reduce the availability of CGRP, and were found effective in reducing the frequency of chronic and episodic migraine. We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons. To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats. Fremanezumab pretreatment selectively inhibited the responsiveness of Aδ neurons, but not C-fiber neurons, as reflected in a decrease in the percentage of neurons that showed activation by cortical spreading depression. These findings identify Aδ meningeal nociceptors as a likely site of action of fremanezumab in the prevention of headache. The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-δ input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients. SIGNIFICANCE STATEMENT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and sensitization of high-threshold (HT) but not wide-dynamic range trigeminovascular neurons by cortical spreading depression (CSD). In the current paper, we report that CGRP-mAbs prevent the activation of Aδ but not C-type meningeal nociceptors by CSD. This is the first identification of an anti-migraine drug that appears to be selective for Aδ-fibers (peripherally) and HT neurons (centrally). As the main CGRP-mAb site of action appears to be situated outside the brain, we conclude that the initiation of the headache phase of migraine depends on activation of meningeal nociceptors, and that for selected patients, activation of the Aδ-HT pain pathway may be sufficient for the generation of headache perception.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597 · cited 1×
“…evidence for the assertion that the prophylactic effect of CGRP-mAbs is achieved mainly through their ability to prevent the activation of peripheral trigeminovascular neurons of the A type by events that lead to cerebral release of CGRP, such as during migraine headache (Goadsby et al., 1990).”
BackgroundIntrinsic brain activity triggers trigeminal meningeal afferents in a migraine model
Bolay, H., Reuter, U., Dunn, A. K., Huang, Z., Boas, D. A., & Moskowitz, M. A. (2002) · Nature Medicine · doi:10.1038/nm0202-136 · Cited by 1,214 · cited 2×
“…than C-fibers, because CGRP receptors are present on cerebral vascular smooth muscle cells (Eftekhari et al., 2013; Miller et al., 2016), and CSD-induced cerebral vasodilatation (Bolay et al., 2002; Ayata and Lauritzen, 2015) is partly dependent on CGRP (Colonna et al., 1994; Reuter et al., 1998).”
BackgroundThe neurobiology of vascular head pain
Moskowitz, M. A. (1984) · Annals of Neurology · doi:10.1002/ana.410160202 · Cited by 905 · cited 2×
“…but one line of research has focused on its role in the physiology of neurons that supply the sensory innervation of the cranial meninges, a sensory pathway that has been critically implicated in the generation of migraine headache (Moskowitz, 1984; Strassman et al., 1996; Burstein et al., 2015).”
BackgroundMigraine: Multiple Processes, Complex Pathophysiology
Burstein, R., Noseda, R., & Borsook, D. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0373-15.2015 · Cited by 838 · cited 2×
“…but one line of research has focused on its role in the physiology of neurons that supply the sensory innervation of the cranial meninges, a sensory pathway that has been critically implicated in the generation of migraine headache (Moskowitz, 1984; Strassman et al., 1996; Burstein et al., 2015).”
Self-citationSensitization of meningeal sensory neurons and the origin of headaches
Strassman, A. M., Raymond, S. A., & Burstein, R. (1996) · Nature · doi:10.1038/384560a0 · Cited by 703 · cited 2×
“…but one line of research has focused on its role in the physiology of neurons that supply the sensory innervation of the cranial meninges, a sensory pathway that has been critically implicated in the generation of migraine headache (Moskowitz, 1984; Strassman et al., 1996; Burstein et al., 2015).”
BackgroundSelf-citationMigraine Headache Triggered Specifically by Sunlight: Report of 16 Cases
Tekatas, A., & Mungen, B. (2013) · European Neurology · doi:10.1159/000354165 · Cited by 665
Defeating migraine pain with triptans: A race against the development of cutaneous allodynia
Burstein, R., Collins, B., & Jakubowski, M. (2004) · Annals of Neurology · doi:10.1002/ana.10786 · Cited by 602 · cited 1×
“…the pain signals from the nociceptors, and accordingly, proposed that latephase central sensitization and allodynia explain the inferior efficacy of late treatment with drugs that lack the ability to reverse the sensitization(Burstein and Jakubowski, 2004; Burstein et al., 2004; Levy et al., 2004).”
BackgroundSelf-citationSpreading Depression, Spreading Depolarizations, and the Cerebral Vasculature
Ayata, C., & Lauritzen, M. (2015) · Physiological Reviews · doi:10.1152/physrev.00027.2014 · Cited by 555 · cited 2×
“…than C-fibers, because CGRP receptors are present on cerebral vascular smooth muscle cells (Eftekhari et al., 2013; Miller et al., 2016), and CSD-induced cerebral vasodilatation (Bolay et al., 2002; Ayata and Lauritzen, 2015) is partly dependent on CGRP (Colonna et al., 1994; Reuter et al., 1998).”
BackgroundCalcitonin gene-related peptide: functional role in cerebrovascular regulation.
McCulloch, J., Uddman, R., Kingman, T. A., & Edvinsson, L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.15.5731 · Cited by 514 · cited 1×
“Peripherally, CGRP produces meningeal vasodilatation (McCulloch et al., 1986; Uddman et al., 1986; Edvinsson et al., 1987, 1998; Kurosawa et al., 1995; Williamson et al., 1997), and thus contributes to meningeal neurogenic inflammation.”
BackgroundZhang, X., Levy, D., Noseda, R., Kainz, V., Jakubowski, M., & Burstein, R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0511-10.2010 · Cited by 408 · cited 1×
“…was evoked by cortical spreading depression (CSD), a cortical event that has been implicated in the initiation of migraine attacks (Bolay and Moskowitz, 2005) and that is effective in activating both first- and second-order neurons in the meningeal sensory pathway (Zhang et al., 2010, 2011).”
BackgroundSelf-citationActivation of central trigeminovascular neurons by cortical spreading depression
Zhang, X., Levy, D., Kainz, V., Noseda, R., Jakubowski, M., & Burstein, R. (2011) · Annals of Neurology · doi:10.1002/ana.22329 · Cited by 402 · cited 1×
“…was evoked by cortical spreading depression (CSD), a cortical event that has been implicated in the initiation of migraine attacks (Bolay and Moskowitz, 2005) and that is effective in activating both first- and second-order neurons in the meningeal sensory pathway (Zhang et al., 2010, 2011).”
BackgroundSelf-citationCalcitonin Gene-Related Peptide (CGRP): A New Target for Migraine
Russo, A. F. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124701 · Cited by 389 · cited 1×
“A large body of evidence in both man and animals supports an important role for CGRP in the pathophysiology of migraine headache (Hansen and Ashina, 2014; Karsan and Goadsby, 2015; Russo, 2015).”
BackgroundDodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, J., Ashina, M., Wilks, K., Kudrow, D., Kroll, R., Kohrman, B., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70209-1 · Cited by 372 · cited 1×
“As a new approach to migraine treatment, humanized CGRP monoclonal antibodies (CGRP-mAbs) have been developed as therapeutic agents, and were found to reduce the frequency of attacks in chronic migraine patients (Dodick et al., 2014a,b; Bigal et al., 2015a,b; Sun et al., 2016).”
BackgroundDodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368 · cited 1×
“As a new approach to migraine treatment, humanized CGRP monoclonal antibodies (CGRP-mAbs) have been developed as therapeutic agents, and were found to reduce the frequency of attacks in chronic migraine patients (Dodick et al., 2014a,b; Bigal et al., 2015a,b; Sun et al., 2016).”
BackgroundSun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., Saper, J., Cady, R., Chon, Y., Dietrich, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00019-3 · Cited by 358 · cited 1×
“As a new approach to migraine treatment, humanized CGRP monoclonal antibodies (CGRP-mAbs) have been developed as therapeutic agents, and were found to reduce the frequency of attacks in chronic migraine patients (Dodick et al., 2014a,b; Bigal et al., 2015a,b; Sun et al., 2016).”
BackgroundBurstein, R., & Jakubowski, M. (2004) · Annals of Neurology · doi:10.1002/ana.10785 · Cited by 357 · cited 1×
“…the pain signals from the nociceptors, and accordingly, proposed that latephase central sensitization and allodynia explain the inferior efficacy of late treatment with drugs that lack the ability to reverse the sensitization(Burstein and Jakubowski, 2004; Burstein et al., 2004; Levy et al., 2004).”
BackgroundSelf-citationPrice, D. D., Dubner, R., & Hu, J. W. (1976) · Journal of Neurophysiology · doi:10.1152/jn.1976.39.5.936 · Cited by 354
Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects
Uddman, R., Edvinsson, L., Ekblad, E., Håkanson, R., & Sundler, F. (1986) · Regulatory Peptides · doi:10.1016/0167-0115(86)90071-6 · Cited by 323 · cited 1×
“Peripherally, CGRP produces meningeal vasodilatation (McCulloch et al., 1986; Uddman et al., 1986; Edvinsson et al., 1987, 1998; Kurosawa et al., 1995; Williamson et al., 1997), and thus contributes to meningeal neurogenic inflammation.”
BackgroundStorer, R. J., Akerman, S., & Goadsby, P. J. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705807 · Cited by 307 · cited 2×
“, 2000) and the central endings in the medullary and upper cervical dorsal horn (Storer et al., 2004; Fischer et al., 2005).”
BackgroundCalcitonin Gene-Related Peptide and Cerebral Blood Vessels: Distribution and Vasomotor Effects
Edvinsson, L., Ekman, R., Jansen, I., McCulloch, J., & Uddman, R. (1987) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1987.126 · Cited by 304 · cited 1×
“Peripherally, CGRP produces meningeal vasodilatation (McCulloch et al., 1986; Uddman et al., 1986; Edvinsson et al., 1987, 1998; Kurosawa et al., 1995; Williamson et al., 1997), and thus contributes to meningeal neurogenic inflammation.”
BackgroundRoles of capsaicin-insensitive nociceptors in cutaneous pain and secondary hyperalgesia
Magerl, W. (2001) · Brain · doi:10.1093/brain/124.9.1754 · Cited by 297 · cited 1×
“In humans, A fibers, especially the mechanosensitive and mechanoheat-sensitive type I which are also capsaicininsensitive, are the only type of nociceptors that mediate the perception of pinprick (Magerl et al., 2001).”
BackgroundBigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma, Y., Yang, R., Loupe, P. S., Burstein, R., Newman, L. C., & Lipton, R. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00249-5 · Cited by 287 · cited 2×
“Clinically, fremanezumab’s selective inhibition of peripheral A meningeal nociceptors and central HT trigeminovascular neurons may also explain how CGRP-mAbs prevent the headaches, and equally important, why it may not work for everybody (Bigal et al., 2015a,b).”
BackgroundSelf-citationPrice, T. J., & Flores, C. M. (2007) · The Journal of Pain · doi:10.1016/j.jpain.2006.09.005 · Cited by 280 · cited 1×
“Calcitonin gene-related peptide (CGRP) is the most abundant neuropeptide present in primary afferent sensory neurons in dorsal root and trigeminal ganglia (O’Connor and van der Kooy, 1988; McCarthy and Lawson, 1990; Price and Flores, 2007).”
BackgroundBigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E. L. H., Diener, H.-C., Burstein, R., Loupe, P. S., Ma, Y., Yang, R., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00245-8 · Cited by 261 · cited 2×
“Clinically, fremanezumab’s selective inhibition of peripheral A meningeal nociceptors and central HT trigeminovascular neurons may also explain how CGRP-mAbs prevent the headaches, and equally important, why it may not work for everybody (Bigal et al., 2015a,b).”
BackgroundSelf-citationEftekhari, S., Warfvinge, K., Blixt, F. W., & Edvinsson, L. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2013.03.010 · Cited by 260
Levy, D., Jakubowski, M., & Burstein, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306147101 · Cited by 257 · cited 1×
“…the pain signals from the nociceptors, and accordingly, proposed that latephase central sensitization and allodynia explain the inferior efficacy of late treatment with drugs that lack the ability to reverse the sensitization(Burstein and Jakubowski, 2004; Burstein et al., 2004; Levy et al., 2004).”
BackgroundSelf-citationMcCarthy, P. W., & Lawson, S. N. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90169-5 · Cited by 242 · cited 1×
“Calcitonin gene-related peptide (CGRP) is the most abundant neuropeptide present in primary afferent sensory neurons in dorsal root and trigeminal ganglia (O’Connor and van der Kooy, 1988; McCarthy and Lawson, 1990; Price and Flores, 2007).”
BackgroundRegulation of Calcitonin Gene-Related Peptide Secretion by a Serotonergic Antimigraine Drug
Durham, P. L., & Russo, A. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03423.1999 · Cited by 191 · cited 1×
“Among the most well documented effects of the anti-migraine agent sumatriptan is inhibition of neuropeptide release from both the peripheral and central terminals of meningeal sensory neurons (Messlinger et al., 1998; Durham and Russo, 1999; Eltorp et al., 2000).”
BackgroundPeptidergic and serotoninergic innervation of the rat dura mater
Keller, J. T., & Marfurt, C. F. (1991) · Journal of Comparative Neurology · doi:10.1002/cne.903090408 · Cited by 184 · cited 2×
“…is present in a substantial subpopulation of the meningeal sensory neurons (O’Connor and van der Kooy, 1988; Tsai et al., 1988; Uddman et al., 1989; Keller and Marfurt, 1991; Messlinger et al., 1993; Edvinsson et al., 2001), and can be released from both the peripheral endings in the meninges…”
BackgroundSun, R.-Q., Tu, Y.-J., Lawand, N. B., Yan, J.-Y., Lin, Q., & Willis, W. D. (2004) · Journal of Neurophysiology · doi:10.1152/jn.00339.2004 · Cited by 180 · cited 1×
“…released from the central terminals of meningeal sensory neurons has not yet been well elucidated, but there is evidence from studies at spinal levels that CGRP contributes to sensitization of dorsal horn neurons (Sun et al., 2004a,b; Han et al., 2005; Bird et al., 2006; Adwanikar et al., 2007).”
BackgroundHan, J. S., Li, W., & Neugebauer, V. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4112-05.2005 · Cited by 173 · cited 1×
“…released from the central terminals of meningeal sensory neurons has not yet been well elucidated, but there is evidence from studies at spinal levels that CGRP contributes to sensitization of dorsal horn neurons (Sun et al., 2004a,b; Han et al., 2005; Bird et al., 2006; Adwanikar et al., 2007).”
BackgroundWilliamson, D., Hargreaves, R., Hill, R., & Shepheard, S. (1997) · Cephalalgia · doi:10.1046/j.1468-2982.1997.1704518.x · Cited by 170 · cited 1×
“Peripherally, CGRP produces meningeal vasodilatation (McCulloch et al., 1986; Uddman et al., 1986; Edvinsson et al., 1987, 1998; Kurosawa et al., 1995; Williamson et al., 1997), and thus contributes to meningeal neurogenic inflammation.”
BackgroundMelo-Carrillo, A., Noseda, R., Nir, R.-R., Schain, A. J., Stratton, J., Strassman, A. M., & Burstein, R. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0576-17.2017 · Cited by 163 · cited 6×
“Our current and recent (Melo-Carrillo et al., 2017) studies call for a revision of this concept.”
BackgroundInfluentialSelf-citationO'Connor, T., & van der Kooy, D. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-07-02468.1988 · Cited by 161
Kurosawa, M., Meßlinger, K., Pawlak, M., & Schmidt, R. F. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13361.x · Cited by 146 · cited 3×
“Peripherally, CGRP produces meningeal vasodilatation (McCulloch et al., 1986; Uddman et al., 1986; Edvinsson et al., 1987, 1998; Kurosawa et al., 1995; Williamson et al., 1997), and thus contributes to meningeal neurogenic inflammation.”
BackgroundFischer, M. J. M., Koulchitsky, S., & Meßlinger, K. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0869-05.2005 · Cited by 146 · cited 2×
“, 2000) and the central endings in the medullary and upper cervical dorsal horn (Storer et al., 2004; Fischer et al., 2005).”
BackgroundMe�linger, K., Hanesch, U., RTEL, M. B., Trost, B., & Schmidt, R. (1993) · Anatomy and Embryology · doi:10.1007/bf00188214 · Cited by 145 · cited 2×
“CGRP is present in a substantial subpopulation of the meningeal sensory neurons (O’Connor and van der Kooy, 1988; Tsai et al., 1988; Uddman et al., 1989; Keller and Marfurt, 1991; Messlinger et al., 1993; Edvinsson et al., 2001), and can be released from both the peripheral endings in the meninges (Zagami et al.”
BackgroundUddman, R., Hara, H., & Edvinsson, L. I. (1989) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(89)90109-4 · Cited by 114 · cited 2×
“CGRP is present in a substantial subpopulation of the meningeal sensory neurons (O’Connor and van der Kooy, 1988; Tsai et al., 1988; Uddman et al., 1989; Keller and Marfurt, 1991; Messlinger et al., 1993; Edvinsson et al., 2001), and can be released from both the peripheral endings in the meninges (Zagami et al.”
BackgroundEdvinsson, L. I., Mulder, H., Goadsby, P. J., & Uddman, R. (1998) · Journal of the Autonomic Nervous System · doi:10.1016/s0165-1838(98)00033-2 · Cited by 114 · cited 1×
“Peripherally, CGRP produces meningeal vasodilatation (McCulloch et al., 1986; Uddman et al., 1986; Edvinsson et al., 1987, 1998; Kurosawa et al., 1995; Williamson et al., 1997), and thus contributes to meningeal neurogenic inflammation.”
BackgroundAxon diameters and intradural trajectories of the dural innervation in the rat
Strassman, A. M., Weissner, W., Williams, M., Saad, A., & Levy, D. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20106 · Cited by 110 · cited 2×
“Our electrophysiological/functional findings suggest that most dural CLR- and RAMP1-positive A-fibers are thinly myelinated A -fibers; a conclusion supported by anatomical studies showing that almost all A-fibers in the dura are A (Strassman et al., 2004).”
ResultSelf-citationPain-Related Synaptic Plasticity in Spinal Dorsal Horn Neurons: Role of CGRP
Bird, G. C., Han, J. S., Fu, Y., Adwanikar, H., Willis, W. D., & Neugebauer, V. (2006) · Molecular Pain · doi:10.1186/1744-8069-2-31 · Cited by 100 · cited 2×
“The actions of CGRP as a neuromodulator when released from the central terminals of meningeal sensory neurons has not yet been well elucidated, but there is evidence from studies at spinal levels that CGRP contributes to sensitization of dorsal horn neurons (Sun et al., 2004a,b; Han et al., 2005; Bird et al., 2006; Ad…”
BackgroundTsai, S., Tew, J. M., McLean, J. H., & Shipley, M. T. (1988) · The Journal of Comparative Neurology · doi:10.1002/cne.902710310 · Cited by 80 · cited 2×
“CGRP is present in a substantial subpopulation of the meningeal sensory neurons (O’Connor and van der Kooy, 1988; Tsai et al., 1988; Uddman et al., 1989; Keller and Marfurt, 1991; Messlinger et al., 1993; Edvinsson et al., 2001), and can be released from both the peripheral endings in the meninges (Zagami et al.”
BackgroundPerivascular nerves contribute to cortical spreading depression-associated hyperemia in rats
Reuter, U., Weber, J. R., Gold, L., Arnold, G., Wolf, T., Dreier, J. P., Lindauer, U., & Dirnagl, U. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.6.h1979 · Cited by 74 · cited 2×
“…than C-fibers, because CGRP receptors are present on cerebral vascular smooth muscle cells (Eftekhari et al., 2013; Miller et al., 2016), and CSD-induced cerebral vasodilatation (Bolay et al., 2002; Ayata and Lauritzen, 2015) is partly dependent on CGRP (Colonna et al., 1994; Reuter et al., 1998).”
BackgroundMiller, S., Liu, H., Warfvinge, K., Shi, L., Dovlatyan, M., Xu, C., & Edvinsson, L. I. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.04.046 · Cited by 73 · cited 1×
“…a greater effect on A -fibers than C-fibers, because CGRP receptors are present on cerebral vascular smooth muscle cells (Eftekhari et al., 2013; Miller et al., 2016), and CSD-induced cerebral vasodilatation (Bolay et al., 2002; Ayata and Lauritzen, 2015) is partly dependent on CGRP (Colonna et…”
BackgroundLipton, R. B., Munjal, S., Buse, D. C., Bennett, A., Fanning, K. M., Burstein, R., & Reed, M. L. (2017) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13115 · Cited by 73 · cited 1×
“…migraine in patients (i.e., the responders) who are likely to exhibit signs of late-phase, already established, allodynia and central sensitization (Lipton et al., 2017) suggests that their ongoing allodynia and central sensitization continue to depend on the pain signals they receive from the…”
BackgroundSelf-citationCalcitonin gene-related peptide and migraine
Karsan, N., & Goadsby, P. J. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000191 · Cited by 73 · cited 1×
“A large body of evidence in both man and animals supports an important role for CGRP in the pathophysiology of migraine headache (Hansen and Ashina, 2014; Karsan and Goadsby, 2015; Russo, 2015).”
BackgroundThe emerging importance of cortical spreading depression in migraine headache
Bolay, H., & Moskowitz, M. A. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85108-2 · Cited by 62 · cited 1×
“…than C-fibers, because CGRP receptors are present on cerebral vascular smooth muscle cells (Eftekhari et al., 2013; Miller et al., 2016), and CSD-induced cerebral vasodilatation (Bolay et al., 2002; Ayata and Lauritzen, 2015) is partly dependent on CGRP (Colonna et al., 1994; Reuter et al., 1998).”
BackgroundBraz, J. M., & Basbaum, A. I. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.07.051 · Cited by 62 · cited 1×
“…the pain signals from the nociceptors, and accordingly, proposed that latephase central sensitization and allodynia explain the inferior efficacy of late treatment with drugs that lack the ability to reverse the sensitization(Burstein and Jakubowski, 2004; Burstein et al., 2004; Levy et al., 2004).”
BackgroundColonna, D. M., Meng, W., Deal, D. D., & Busija, D. W. (1994) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1994.266.3.h1095 · Cited by 60 · cited 2×
“…than C-fibers, because CGRP receptors are present on cerebral vascular smooth muscle cells (Eftekhari et al., 2013; Miller et al., 2016), and CSD-induced cerebral vasodilatation (Bolay et al., 2002; Ayata and Lauritzen, 2015) is partly dependent on CGRP (Colonna et al., 1994; Reuter et al., 1998).”
BackgroundCalcitonin gene-related peptide and migraine with aura: A systematic review
Hansen, J. M., & Ashina, M. (2014) · Cephalalgia · doi:10.1177/0333102413520084 · Cited by 32 · cited 1×
“A large body of evidence in both man and animals supports an important role for CGRP in the pathophysiology of migraine headache (Hansen and Ashina, 2014; Karsan and Goadsby, 2015; Russo, 2015).”
BackgroundAdwanikar, H., Ji, G., Li, W., Doods, H. N., Willis, W. D., & Neugebauer, V. (2007) · Pain · doi:10.1016/j.pain.2007.01.024 · Cited by 32 · cited 1×
“…than C-fibers, because CGRP receptors are present on cerebral vascular smooth muscle cells (Eftekhari et al., 2013; Miller et al., 2016), and CSD-induced cerebral vasodilatation (Bolay et al., 2002; Ayata and Lauritzen, 2015) is partly dependent on CGRP (Colonna et al., 1994; Reuter et al., 1998).”
Background
Cited by
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
Migraine and the trigeminovascular system—40 years and counting
Ashina, M., Hansen, J. M., Do, T. P., Melo-Carrillo, A., Burstein, R., & Moskowitz, M. A. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30185-1 · Cited by 606
Self-citationDodick, D. W. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30478-1 · Cited by 557
Ferrari, M. D., Goadsby, P. J., Burstein, R., Kurth, T., Ayata, C., Charles, A., Ashina, M., van den Maagdenberg, A. M. J. M., & Dodick, D. W. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00328-4 · Cited by 500
Self-citationCGRP and the Trigeminal System in Migraine
Iyengar, S., Johnson, K. W., Ossipov, M. H., & Aurora, S. K. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13529 · Cited by 486
Metadata
- Authors
- Melo-Carrillo, A., Strassman, A. M., Nir, R.-R., Schain, A. J., Noseda, R., Stratton, J., & Burstein, R.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2017-09-29
- Volume
- 37
- Issue
- 44
- Pages
- 10587-10596
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2760684802
- Cited by
- 189
- References
- 51
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.